Fate Therapeutics presented late-breaking preclinical data highlighting the company’s “unmatched ability to mass produce uniformly engineered chimeric antigen receptor T cells for off-the-shelf cancer immunotherapy” at the American Association of Cancer Research Annual Meeting 2019 in Atlanta, Georgia. New preclinical data presented at AACR for FT819, the company’s universal, off-the-shelf CAR19 T-cell product candidate being developed under a collaboration with Memorial Sloan Kettering Cancer Center led by Michel Sadelain, M.D., Ph.D., demonstrate the production of clonal master engineered iPSC lines having complete elimination of T-cell receptor expression and insertion of a novel 1XX CAR signaling domain into the T-cell receptor alpha locus. These synthetic features are intended to mitigate the risk of graft-versus-host disease, a severe life-threatening condition that occurs when donor T cells attack a patient’s healthy tissue, and to regulate CAR expression to enhance the therapeutic profile of CAR T cells.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.